Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Prodia Widyahusada TbkPRWDF 74 3-Year Revenue Growth Rate is 2.70% as of Jun. 2026, which is 65% below its 10-year median of 7.80. GuruFocus rates PRWDF with a GF Score™ of 74/100. The stock has 1 warning sign investors should review. Among 190 Medical Diagnostics & Research companies, PT Prodia Widyahusada Tbk ranks better than 51.58% on this metric.
During the past 12 months, PT Prodia Widyahusada Tbk's average Revenue per Share Growth Rate was 10.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 2.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 2.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 6.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of PT Prodia Widyahusada Tbk was 18.80% per year. The lowest was -5.00% per year. And the median was 7.80% per year.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
PT Prodia Widyahusada Tbk 3-Year Revenue Growth Rate Related Terms
PRWDF vs TMO, DHR, NTRA: 3-Year Revenue Growth Rate Comparison
For the Diagnostics & Research subindustry, PT Prodia Widyahusada Tbk's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Prodia Widyahusada Tbk 3-Year Revenue Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, PT Prodia Widyahusada Tbk's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where PT Prodia Widyahusada Tbk's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of 2.70% mean?
PT Prodia Widyahusada Tbk (PRWDF) has a 3-Year Revenue Growth Rate of 2.70% as of Jun. 2026. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for PT Prodia Widyahusada Tbk and its competitors. This is 65% below median its historical median of 7.80. According to the industry distribution chart, PT Prodia Widyahusada Tbk ranks #92 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 48.4%.
Is PT Prodia Widyahusada Tbk's 3-Year Revenue Growth Rate too high?
PT Prodia Widyahusada Tbk's current 3-Year Revenue Growth Rate of 2.70% is 65% below median its 10-year median of 7.80. The Medical Diagnostics & Research industry median 3-Year Revenue Growth Rate is 1.70. PT Prodia Widyahusada Tbk's value of 2.70% is 58.8% above this industry median. Based on the distribution chart, PT Prodia Widyahusada Tbk ranks #92 out of 190 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, PT Prodia Widyahusada Tbk has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does PT Prodia Widyahusada Tbk's 3-Year Revenue Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, PT Prodia Widyahusada Tbk ranks #92 out of 190 companies for 3-Year Revenue Growth Rate. This puts PT Prodia Widyahusada Tbk in the upper half of its industry. The industry median 3-Year Revenue Growth Rate is 1.70. PT Prodia Widyahusada Tbk's value of 2.70% is 58.8% above this benchmark. While the company's 10-year median is 7.80 vs. the industry median of 1.70, PT Prodia Widyahusada Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year Revenue Growth Rate among Medical Diagnostics & Research companies is 1.70, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Prodia Widyahusada Tbk's current 3-Year Revenue Growth Rate of 2.70% is 58.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for PT Prodia Widyahusada Tbk and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year Revenue Growth Rate is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Prodia Widyahusada Tbk's current 3-Year Revenue Growth Rate is 2.70%, which is 65% below median its own 10-year median of 7.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Prodia Widyahusada Tbk stock overvalued right now?
PT Prodia Widyahusada Tbk (PRWDF) has a current 3-Year Revenue Growth Rate of 2.70%. The current 3-Year Revenue Growth Rate is 2.70%, which is 65% below median its 10-year median of 7.80 and 58.8% above the Medical Diagnostics & Research industry median of 1.70. PT Prodia Widyahusada Tbk's overall GF Score™ is 74/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For PT Prodia Widyahusada Tbk (PRWDF), the current 3-Year Revenue Growth Rate is 2.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PT Prodia Widyahusada Tbk provides health care testing services. The company provides analytic and diagnostic services for the medical professionals. It is engaged in health laboratories by conducting business activities such as setting up clinics, health laboratories, management of hospitals, and health checkup services. Its operating segments are Central: Jakarta; Sumatera: Sumatera, Kepulauan Riau; Greater Jakarta: Jakarta, Bogor, Depok, Tangerang, Bekasi, Lampung, Pangkal Pinang; West Java; Central Java; East Java, Bali, Nusa Tenggara; Kalimantan Sulampua: Kalimantan, Sulawesi, Ambon, Papua.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRWDF has been successfully added to your 
